Department of Molecular Neurobiology, Tokyo Metropolitan Institute for Neuroscience, Tokyo Metropolitan Organization for Medical Research, Fuchu, Tokyo, Japan.
EMBO Mol Med. 2010 Dec;2(12):504-15. doi: 10.1002/emmm.201000103.
Apoptosis signal-regulating kinase 1 (ASK1) is an evolutionarily conserved mitogen-activated protein kinase (MAPK) kinase kinase which plays important roles in stress and immune responses. Here, we show that ASK1 deficiency attenuates neuroinflammation in experimental autoimmune encephalomyelitis (EAE), without affecting the proliferation capability of T cells. Moreover, we found that EAE upregulates expression of Toll-like receptors (TLRs) in activated astrocytes and microglia, and that TLRs can synergize with ASK1-p38 MAPK signalling in the release of key chemokines from astrocytes. Consequently, oral treatment with a specific small molecular weight inhibitor of ASK1 suppressed EAE-induced autoimmune inflammation in both spinal cords and optic nerves. These results suggest that the TLR-ASK1-p38 pathway in glial cells may serve as a valid therapeutic target for autoimmune demyelinating disorders including multiple sclerosis.
凋亡信号调节激酶 1(ASK1)是一种进化上保守的丝裂原活化蛋白激酶(MAPK)激酶激酶,在应激和免疫反应中发挥重要作用。在这里,我们表明 ASK1 缺乏可减轻实验性自身免疫性脑脊髓炎(EAE)中的神经炎症,而不影响 T 细胞的增殖能力。此外,我们发现 EAE 可在上皮细胞和小胶质细胞中上调 Toll 样受体(TLR)的表达,并且 TLR 可与 ASK1-p38 MAPK 信号通路协同作用,从星形胶质细胞中释放关键趋化因子。因此,口服使用 ASK1 的特异性小分子抑制剂可抑制脊髓和视神经中 EAE 诱导的自身免疫炎症。这些结果表明,胶质细胞中的 TLR-ASK1-p38 途径可能是包括多发性硬化症在内的自身免疫性脱髓鞘疾病的有效治疗靶点。